Internal medicine

Receptor

Muscarinic antagonist

Agonist

Inhaler

Bronchodilator

Muscarinic acetylcholine receptor

Asthma

COPD

Antagonist

Inhalation

Indacaterol

Glucocorticoid

Lama

Pulmonary disease

Anesthesia

Medicine

New England Journal of Medicine

The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid–LABA or LAMA–LABA), are uncertain.

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD